Cancer Mission
Risultati e bandi del 2023

Giovanni Apolone
Direttore Scientifico– INT
Presidente Eletto – OECI
Coordinatore progetti call 2021 02-02, 2022 01-02

Fondazione IRCCS
Istituto Nazionale dei Tumori
Sistema Socio Sanitario
Regione Lombardia

Outline

- Le call 2022-2024
- Focus sul 2022
- Performance partecipazione Italia in CM
- Le call del 2023
- L’esperienza di INT
- Qualche riflessione

Le Call della CM

	2021	2022	2023
No.	4	5	4
Budget	128.65	126	110.68

2022 CALL TOPICS – General Statistics



MISSION CANCER 2021+2022 | I primi bandi

8 BANDI
• HORIZON-MISS-2021-UNCAN-01-01
• HORIZON-MISS-2021-CANCER-02-01
• HORIZON-MISS-2021-CANCER-02-02
• HORIZON-MISS-2021-CANCER-02-03
• HORIZON-MISS-2022-CANCER-01-01
• HORIZON-MISS-2022-CANCER-01-02
• HORIZON-MISS-2022-CANCER-01-03
• HORIZON-MISS-2022-CANCER-01-05

PERFORMANCE IT	
TASSO DI SUCCESSO IT #	18 %
TASSO DI SUCCESSO IT €	14 %

APREdati

MISSION CANCER 2021 + 2022 |
COMPETIZIONE EUROPEA – TOP SEVEN

Paesi	# Partecipazione	€ Contributo finanziario	# Rientro	€ Rientro
BE	79	46.727.357 €	10%	13%
ES	106	41.518.409 €	13%	12%
FR	70	39.306.305 €	8%	10.9%
IT	**81**	**38.028.979 €**	**10%**	**10.6%**
DE	72	37.827.567 €	9%	10.5%
IL	31	31.509.835 €	4%	9%
EL	41	22.372.868 €	5%	6%

ITALIA #
2° posto

ITALIA €
4° posto

MISSION CANCER 2021 + 2022 |
COORDINAMENTI –TOP SEVEN

Paesi	# Coordinamenti	€ Contributo finanziario
BE	6	19.771.322 €
IT	**7**	**15.812.839 €**
IL	6	14.359.700 €
EL	6	8.477.333 €
FR	5	6.891.748 €
ES	5	5.757.679 €
DE	3	4.687.948 €

ITALIA #
1° posto

ITALIA €
2° posto

MISSION CANCER 2021 + 2022 |
PERFORMANCE per TOPIC (partecipazioni | Eu Contrib



Le call del 2023

Call - Research and Innovation actions supporting the implementation of the Mission on Cancer

HORIZON-MISS-2023-CANCER-01

Topics	Type of Action	Budgets (EUR million)	Expected EU contribution per project (EUR million)[2]	Indicative number of projects expected to be funded
		2023		
Opening: 12 Jan 2023 Deadline(s): 12 Apr 2023				
HORIZON-MISS-2023-CANCER-01-01	RIA	36.68 [3]	7.00 to 12.00	4
HORIZON-MISS-2023-CANCER-01-02	RIA	25.00 [4]	4.00 to 6.00	5
HORIZON-MISS-2023-CANCER-01-03	RIA	43.00 [5]	6.00 to 8.00	7
HORIZON-MISS-2023-CANCER-01-04	IA	6.00 [6]	Around 6.00	1
Overall indicative budget		110.68		

Le call del 2023:Titoli

HORIZON-MISS-2023-CANCER-01-01: Addressing poorly-understood tumour-host interactions to enhance immune system-centred treatment and care interventions in childhood, adolescent, adult and elderly cancer patients.

HORIZON-MISS-2023-CANCER-01-02: Enhance primary cancer prevention through sustainable behavioural change

HORIZON-MISS-2023-CANCER-01-03: Pragmatic clinical trials on minimally invasive diagnostics

HORIZON-MISS-2023-CANCER-01-04: Establish best practices and tools to improve the quality of life for childhood cancer patients, survivors and their families in European regions

INT EU funded projects

27 projects ongoing

18 funded in 2022

ALL

22 partners

5 coordinators

CM

6 Partners

2 Coordinators

INT - PROGETTI MISSION CANCER FINANZIATI

Principal Investigator	Finanziamento	Acronimo	Ruolo	Titolo progetto
G. APOLONE	€ 1.913.271,00	EUonQOL	Coordinatore	Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe
A. FERRARI	€ 200.003,00	MELCAYA	Partner	Novel health care strategies for melanoma in children, adolescents and young adults
F. DE BRAUD*	€ 351.875,00	CCI4EU	Partner	Comprehensive Cancer Infrastructures for Europe
G. APOLONE	€ 127.000,00	ECHOS	Partner	Establishing of Cancer Mission Hubs: Networks and Synergies
G. PROCOPIO	€ 371.250,00	CARE1	Partner	First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma
A. GRONCHI	€ 108.750,00	STREXIT	Partner	A pragmatic clinical study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with high risk retroperitoneal sarcoma

*Coordinato da G.Apolone, per conto di OECI

COMPREHENSIVE CANCER INFRASTRUCTURE IN EUROPE (CCI4EU)

Call: HORIZON-MISS-2022-CANCER-01 **Topic**: HORIZON-MISS-2022-CANCER-01-02 **Type of action**: CSA
Project Title: Comprehensive Cancer Infrastructure in Europe (**CCI4EU**)
Start/End Date: 1/05/2023 – 30/04/2026 **Total Requested Budget:** 9.984.080,00€
Coordination: OECI (G.Apolone)

European initiative, implemented in all Member States, based on a capacity building programme (CBP), will help reduce inequalities, in the context of other actions ongoing, such as *CRANE, JANE and UNCAN*.

.

The **CSA will implement the following steps**:

- define CCI Maturity Model including quality indicators;
- profile the CCIs in each MS and a few ACs in terms of CCI presence and levels of maturity; design tailored CBP interventions, giving priority to MSs without any CCI;
- deliver online training courses open to teams in all MSs and ACs, implement targeted onsite interventions;
- scale up and sustain development; disseminate, exploit and report results.



EUonQOL:measuring what matter for cancer patients

Call Topic: HORIZON-MISS-2021- CANCER-02-02

Starting date:	*1 January 2023*
End date:	*31 December 2026*
Duration:	*48 months*
Costs:	*€ 11,081,626.00*
EU contribution:	*€ 10,607,311.00*
Partners:	*23*
Third parties:	*28*



The overall goal is to be instrumental to the progress of the Mission on Cancer plan, with the specific aim of *developing, piloting, validating, and exploiting* the European Oncology Quality of Life toolkit (EUonQoL-Kit) among European cancer patients and survivors. The project will be based on participatory co-design principles through the involvement of patients and their caregivers



Coordinator

Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy

13 Countries	26 Partner/Affiliated/Associated Partner
Austria	Medical University of Innsbruck (MUI)
Belgium	Digital Institute For Cancer Outcomes Research (DIGICORE)
	European Organisation for Research and Treatment of Cancer AISBL (EORTC)
	European Association of Palliative Care (EAPC)
	European Cancer Organisation (ECO)
	Organisation of European Cancer Institutes (OECI)
Bulgaria	Association of Cancer Patients and Friends (APOZ)
Denmark	Region Hovedstaden (RH)
Estonia	Sporedata OÜ (SPOREDATA)
France	Institut Curie (CURIE)
	Institut Gustave Roussy (GR)
	Unicancer (UNICANCER)
Germany	Deutsches Krebsforschungszentrum Heidelberg (DFKZ)
Italy	Alleanza Contro il Cancro (ACC)
	Federazione Italiana delle Associazioni di Volontariato in Oncologia (FAVO)
	Istituto Europeo di Oncologia (IEO)
	Istituto Nazionale Tumori Fondazione Pascale (INT-NA)
	Istituti Fisioterapici Ospitalieri (IFO)
	Universita Degli Studi di Milano (UMIL)
Norway	Oslo Universitetssykehus Hf (OUS)
Romania	Asociatiilor Bolnavilor de Cancer (FABC)
Spain	Fundacio Institut Mar d'Investigacions Mediques (IMIM)
The Netherlands	Stichting Het Nederlands Kanker Instituut-Anton (NKI)
	Stichting Nederlands Instituut Voor Onderzoek Van De Gezondheidszorg (NIVEL)
United Kingdom	University of Leeds (UNIVLEEDS)
	Leeds Teaching Hospital Trust's (LTHT)

INT: qualche riflessione

- Notevole incremento della partecipazione a call EU negli ultimi 3 anni
  - Effetto Piano Strategico Ricerca
  - Presenza di un continuum della ricerca
- Aumento successo come partner e come coordinator
  - Massa critica e qualità ricercatori
  - Qualità e potenziamento Grant Office
  - Acquisizione società esterna di supporto
- Impatto (negativo) su uffici amministrativi INT